Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates
1. Novavax showcased promising preclinical data for H5N1 vaccine candidate. 2. Single doses induced protective antibody responses in nonhuman primates. 3. Vaccine may protect against H5N1 variants, enhancing its market potential. 4. Novavax plans to pursue funding and partnerships for the H5N1 vaccine. 5. Stock rose 5.61% following positive data announcement.